Quest Diagnostics Incorporated

DGX Healthcare Diagnostics & Research

Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024.

Revenue
+9.98%
EPS
+29.4%
Free cash flow
+6.21%
Total debt
−2.20%

Quarter to September 2026, against a year earlier

254.25 1.43 −0.56%
Market cap
$28.0B
P/E
25.0×
Fwd P/E
24.4×
Dividend yield
1.33%
F-score
8/9
Altman Z
3.15
Beneish M
−2.65
Dividend safety
85/100

Quest Diagnostics Incorporated (DGX) Operating cash flow

Alert me on Operating cash flow

Quest Diagnostics Incorporated's operating cash flow for fiscal 2025 was $1.9B, up 41.4% from $1.3B in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.0B. Over the past ten years it has ranged from $821.0M (fiscal 2015) to $2.2B (fiscal 2021); the current reading is higher than 82% of that period. Quest Diagnostics Incorporated ranks 4th of 49 Diagnostics & Research companies by operating cash flow.

Operating cash flow, annual

Embed this chart

Annual newest first

Period Operating cash flow Change
FY2025 $1.9B 41.38%
FY2024 $1.3B 4.87%
FY2023 $1.3B (25.96%)
FY2022 $1.7B (23.06%)
FY2021 $2.2B 11.37%
FY2020 $2.0B 61.30%
FY2019 $1.2B 3.58%
FY2018 $1.2B 2.13%
FY2017 $1.2B 5.29%
FY2016 $1.1B 35.93%

Quarterly newest first

Period Operating cash flow Change
Sep 2026 $611.0M 2.35%
Jun 2026 $597.0M 114.75%
Mar 2026 $278.0M (40.22%)
Dec 2025 $465.0M (17.41%)
43 more quarters

Against its own ten years

Low $821.0M High $2.2B
Ten-year median $1.3B
Current reading's percentile 82

Operating cash flow against peers

What Operating cash flow is

Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.

Reported line item

The full definition of Operating cash flow →

More on DGX